Therapy for diabetes using stem cell migration agent
AssigneeBiozipcode, Inc.
InventorsHideto Kojima, Tomoya Terashima, Miwako Katagi
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides diagnosis of diabetes and/or diabetes-related diseases and disorders and/or symptoms, or the risk thereof, using abnormal stem cell migration and/or residence as an indicator.
Claims15
-16. (canceled)
A method for treating and/or preventing diabetes mellitus or a disease, disorder, and/or symptom associated with diabetes mellitus in a subject, the method comprising:
- administering an effective amount of an agent that reduces or eliminates an abnormal hematopoietic stem cell (HSC) and a stem cell migration agent to the subject.
A method for using a migration and/or residual state of an abnormal hematopoietic stem cell (HSC) as an indicator of treatment for treating and/or preventing diabetes mellitus or diabetes mellitus and/or a disease, disorder, and/or symptom associated with diabetes mellitus in a subject, the method comprising:
- detecting the migration and/or residual state of the abnormal hematopoietic stem cell (HSC) in the subject.
Dependencies are inferred from the claim text.